Figure 4
From: Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine
Combination therapy enhanced the cytotoxic effects of CTLs against cancer cells.
T cells derived from the spleens of the combined vaccine were tested against LL/2, MS1, EL4 and mouse fibroblast cells (NIH-3T3) at different effector/target ratios using a standard chromium 51Cr release assay. T cells isolated from the spleens of mice treated with the combined vaccine exhibited higher cytotoxicity against LL/2 cells than those from the spleens of controls at a 60:1 effector/target cell ratio (A). T cells were able to lyse LL/2, MS1 and EL4 cells (B). The cytotoxicity was blocked completely by anti-CD8 (p < 0.001, variance test) and partly by anti-CD4 mAbs (C). (p < 0.05, variance test).
